98592-34-8

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 2-chloro-4-cyanobenzoate is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique chemical structure allows for the development of new drugs with specific therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, Methyl 2-chloro-4-cyanobenzoate serves as an essential intermediate for the production of pesticides and other crop protection agents. Its incorporation into these products helps enhance their effectiveness in controlling pests and diseases.
Safety Precautions:
Given its potential hazards, Methyl 2-chloro-4-cyanobenzoate should be stored and handled according to proper safety protocols. This includes using personal protective equipment, such as gloves and goggles, to minimize skin and eye contact, as well as ensuring proper ventilation to reduce inhalation risks.

Upstream product

• 220603-20-3 2-Chloro-terephthalamic acid methyl ester 
• 46004-37-9 methyl 4-amino-2-chlorobenzoate 
• 185312-82-7 4-bromo-2-chlorobenzoic acid methyl ester 
• 557-21-1 zinc(II) cyanide 
• 2457-76-3 4-amino-2-chlorobenzoic acid 
• 773837-37-9 sodium cyanide 
• 557-21-1 dicyanozinc 
• 544-92-3 copper(I) cyanide 

Downstream Products

• 911314-17-5 methyl 2-chloro-4-(1H-tetrazol-5-yl)benzoate 
• 108244-57-1 methyl 4-[amino(hydroxyimino)methyl]-2-chlorobenzoate 
• 1418297-98-9 (E)-2-chloro-4-(N'-hydroxycarbamimidoyl)benzoic acid 
• 1418293-52-3 2-chloro-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzoic acid 
• 911314-18-6 Methyl 2-chloro-4-(2-methyl-2H-tetrazol-5-yl)benzoate 
• 220603-21-4 2-Chloro N-(1-dimethylaminoethylidene)-terephthalamic acid methyl ester 
• 117738-77-9 2-chloro-4-cyanobenzoic acid 
• 220603-26-9 {2-Chloro-4-[1-(4-methoxy-benzyl)-5-methyl-1H-[1,2,4]triazol-3-yl]-phenyl}-(6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepin-6-yl)-methanone 
• 220603-23-6 chloro-4-[1-(4-methoxy-benzyl)-5-methyl-1H-[1,2,4]triazol-3-yl]-benzoic acid methyl ester 
• 220603-24-7 2-Chloro-4-[1-(4-methoxy-benzyl)-5-methyl-1H-[1,2,4] triazol-3-yl]-benzoic acid 
• 220603-25-8 2-Chloro-4-[1-(4-methoxy-benzyl)-5-methyl-1H-[1,2,4] triazol-3-yl]-benzoyl chloride 
• 220603-22-5 2-Chloro-4-(5-methyl-1H-[1,2,4] triazol-3-yl)-benzoic acid methyl ester 
• 220603-20-3 2-Chloro-terephthalamic acid methyl ester 

Relevant academic research and scientific papers

NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE

The invention relates to novel trifluoromethyl-oxadiazole derivatives of formula (I), and pharmaceutically acceptable salts thereof, (I) in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, pharmaceutical combinations thereof, and their use as medicaments, particularly for the treatment of neurodegeneration, muscle atrophy or metabolic syndrome via inhibition of HDAC4.

Subtlety of the Structure-Affinity and Structure-Efficacy Relationships around a Nonpeptide Oxytocin Receptor Agonist

Very few nonpeptide oxytocin agonists have currently been reported, and none of them seem suitable for the in vivo investigation of the oxytocin mediated functions. In an attempt to rationalize the design of better tools, we have systematically studied the structural determinants of the affinity and efficacy of representative ligands of the V1a, V2, and OT receptor subtypes. Despite apparently obvious similarity between the ligand structures on one hand, and between the receptor subtypes on the other hand, the binding affinity and the functional activity profiles of truncated and hybrid ligands highlight the subtlety of ligand-receptor interactions for obtaining nonpeptide OT receptor agonists.

OXADIAZOLE DERIVATIVES

The invention relates to compounds of formula (I); wherein R1, R2, Ra, Rb, W, Q and S have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple

OXADIAZOLE DERIVATIVES

The invention relates to compounds of formula (I): wherein R1, R2, Ra, Rb, W, Q and S have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.

New benzylureas as a novel series of potent, nonpeptidic vasopressin V2 receptor agonists

Vasopressin (AVP) is a hormone that stimulates an increase in water permeability through activation of V2 receptors in the kidney. The analogue of AVP, desmopressin, has proven an effective drug for diseases where a reduction of urine output is desired. However, its peptidic nature limits its bioavailability. We report herein the discovery of potent, nonpeptidic, benzylurea derived agonists of the vasopressin V2 receptor. We describe substitutions on the benzyl group to give improvements in potency and subsequent modifications to the urea end group to provide improvements in solubility and increased oral efficacy in a rat model of diuresis. The lead compound 20e (VA106483) is reported for the first time and has been selected for clinical development.

UREA DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE OF THESE

Urea derivatives represented by the following general formula (I) : which have an agonism of V2 receptor, are useful as agents for the treatment or prevention of diabetes insipidus, nocturia, nocturnal enuresis, overactive bladder or the like. In the form

Piperazines as oxytocin agonists

Disclosed are novel compounds according to general formula I, which have shown OT agonist activity.

FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS

The present invention provides a method for treating a thrombotic or an inflammatory disorder administering to a patient in need thereof a therapeutically effective amount of at least one compound of Formula (I) or Formula (V): (I) [INSERTCHEMICAL STRUCTURE HERE] (V)[INSERT CHEMICAL STRUCTURE HERE] or a stereoisomer or pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L, Z, R3, R4, R6, R11, X1, X2, and X3 are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also provides compounds within the scope of Formula I and relates to pharmaceutical compositions comprising these compounds.

Vasopressin agonist formulation and process

This invention provides novel formulations for vasopressin agonist compounds, or a pharmaceutically acceptable salt thereof, having the general structure: and processes for making them, the formulations comprising from about 1% to about 20% of active ingredient, from about 1% to about 18% of a surfactant component, from about 50% to about 80% of a component of one or more polyethylene glycols, from about 1% to about 20% of a component of one or more sucrose fatty acid esters and/or polyvinylpyrrolidone and, optionally, one or more preservatives or antioxidants.